Skip to main content

Table 1 Baseline characteristics of the patients

From: Right ventricular dysfunction is a predictor of non-response and clinical outcome following cardiac resynchronization therapy

Age, years

65.3 ± 12.5

Male gender

46 (76.7%)

Heart failure, aetiology

 

   Dilated cardiomyopathy

27 (45.0%)

   Ischaemic

29 (48.3%)

   Valvular

3 (5.0%)

   Congenital

1 (1.7%)

Rhythm

 

   Sinus

46 (76.7%)

   Atrial fibrillation

13 (21.7%)

   Atrial flutter

1 (1.7%)

Medication

 

   Beta-blockers

43 (71.7%)

   ACE inhibitors/ARB

58 (96.7%)

   Aldosterone antagonists

39 (65.0%)

   Loop diuretics

52 (86.7%)

   Digoxin

12 (20.0%)

   Aspirin

23 (38.3%)

   Warfarin

19 (31.7%)

   Statin

30 (50.0%)

ECG

 

   QRS width (ms)

156 ± 21

Heart rate

 

   Beats per minute (bpm)

76 ± 15

Blood pressure

 

   Systolic (mmHg)

120 ± 20

   Diastolic (mmHg)

72 ± 13

Left ventricle

 

   EDV (mL/m2)

169 ± 62

   ESV (mL/m2)

124 ± 55

   EF (%)

27 ± 8

   Mass (g/m2)

113 ± 30

Right ventricle

 

   EDV (mL/m2)

82 (65-123)

   ESV (mL/m2)

38 (27-76)

   EF (%)

52 (37-62)

   TAPSE (mm)

13.5 ± 5.6

   Peak wall thickness (mm)

3.6 ± 0.9

Pulmonary artery pressure (mmHg)

38.7 ± 8.7

Late gadolinium enhancement

 

   Absent

20 (33.3%)

   Subendocardial

19 (31.7%)

   Subendocardial + mid-wall

6 (10.0%)

   Mid-wall

15 (25.0%)

   Right ventricle

5 (8.3%)

  1. Data is presented as n (%), mean ± SD, or median (25th - 75th percentile). NYHA = New York Heart Association; ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BNP = B-type natriuretic peptide; EDV = End-diastolic volume; ESV = End-systolic volume; EF = Ejection fraction; TAPSE = tricuspid annular plane systolic excursion.